- Home
- IMA vs PDSB Comparison
IMA vs PDSB Comparison
Compare IMA & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMA
- PDSB
- Stock Information
- Founded
- IMA 2019
- PDSB 2005
- Country
- IMA United States
- PDSB United States
- Employees
- IMA N/A
- PDSB N/A
- Industry
- IMA Biotechnology: Biological Products (No Diagnostic Substances)
- PDSB Biotechnology: Pharmaceutical Preparations
- Sector
- IMA Health Care
- PDSB Health Care
- Exchange
- IMA Nasdaq
- PDSB Nasdaq
- Market Cap
- IMA 69.5M
- PDSB 72.2M
- IPO Year
- IMA N/A
- PDSB N/A
- Fundamental
- Price
- IMA N/A
- PDSB $1.09
- Analyst Decision
- IMA
- PDSB Strong Buy
- Analyst Count
- IMA 0
- PDSB 2
- Target Price
- IMA N/A
- PDSB $10.00
- AVG Volume (30 Days)
- IMA 45.7K
- PDSB 473.2K
- Earning Date
- IMA 01-01-0001
- PDSB 08-12-2025
- Dividend Yield
- IMA N/A
- PDSB N/A
- EPS Growth
- IMA N/A
- PDSB N/A
- EPS
- IMA N/A
- PDSB N/A
- Revenue
- IMA N/A
- PDSB N/A
- Revenue This Year
- IMA N/A
- PDSB N/A
- Revenue Next Year
- IMA N/A
- PDSB N/A
- P/E Ratio
- IMA N/A
- PDSB N/A
- Revenue Growth
- IMA N/A
- PDSB N/A
- 52 Week Low
- IMA $11.65
- PDSB $0.85
- 52 Week High
- IMA $23.28
- PDSB $4.29
- Technical
- Relative Strength Index (RSI)
- IMA N/A
- PDSB 36.06
- Support Level
- IMA N/A
- PDSB $1.12
- Resistance Level
- IMA N/A
- PDSB $1.27
- Average True Range (ATR)
- IMA 0.00
- PDSB 0.09
- MACD
- IMA 0.00
- PDSB -0.00
- Stochastic Oscillator
- IMA 0.00
- PDSB 26.92
About PDSB PDS Biotechnology Corporation
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.